Mesothelin and immunotherapy for pancreatic cancer
10.3760/cma.j.issn.1674-6090.2019.06.015
- VernacularTitle: 间皮素与胰腺癌的免疫治疗
- Author:
Xiang GAO
1
;
Quan LIAO
Author Information
1. Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
- Publication Type:Review
- Keywords:
Mesothelin;
Pancreatic cancer;
Immunotherapy
- From:
Chinese Journal of Endocrine Surgery
2019;13(6):510-513
- CountryChina
- Language:Chinese
-
Abstract:
As one of the most lethal malignancies, pancreatic cancer and its therapy remains a big problem all around the world. With the few candidates for surgery and the poor outcome for chemotherapy, the immunotherapy becomes one important direction. Mesothelin, a membrane protein, expresses at low levels in normal tissues, but is re-expressed at a high frequency in pancreatic cancer, which makes mesothelin an ideal target for immunotherapy.This review summarizes the progression of mesothein-targeted immunotherapy for pancreatic cancer.
